Your browser doesn't support javascript.
loading
Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury.
Fernández-Gordón Sánchez, Flor M; Gómez-Domínguez, Elena; Paredes Ruiz, Diana; Rodríguez Gil, Yolanda; Martín Algíbez, Ana; Fernández Vázquez, Inmaculada; Martínez Montiel, Pilar.
Afiliação
  • Fernández-Gordón Sánchez FM; Digestive Diseases, Hospital Universitario 12 de Octubre, España.
  • Gómez-Domínguez E; Digestive Diseases, Hospital Universitario 12 de Octubre.
  • Paredes Ruiz D; Internal Medicine, Hospital Universitario 12 de Octubre.
  • Rodríguez Gil Y; Pathology, Hospital Universitario 12 de Octubre.
  • Martín Algíbez A; Digestive Diseases, Hospital Universitario 12 de Octubre.
  • Fernández Vázquez I; Digestive Diseases, Hospital Universitario 12 de Octubre.
  • Martínez Montiel P; Digestive Diseases, Hospital Universitario 12 de Octubre.
Rev Esp Enferm Dig ; 114(6): 356-357, 2022 06.
Article em En | MEDLINE | ID: mdl-35073724
ABSTRACT
Pembrolizumab, a programmed cell death receptor (PD-1) inhibitor, have improved the prognosis in several types of cancer. Despite the important clinical benefits, checkpoint inhibition have been associated with inflammatory and immune-related side effects (irAE).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite / Doenças do Sistema Imunitário Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite / Doenças do Sistema Imunitário Idioma: En Ano de publicação: 2022 Tipo de documento: Article